These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485 [TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817 [TBL] [Abstract][Full Text] [Related]
30. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387 [No Abstract] [Full Text] [Related]
31. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914 [TBL] [Abstract][Full Text] [Related]
32. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726 [TBL] [Abstract][Full Text] [Related]
33. Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. de Klerk LK; Patel AK; Derks S; Pectasides E; Augustin J; Uduman M; Raman N; Akarca FG; McCleary NJ; Cleary JM; Rubinson DA; Clark JW; Fitzpatrick B; Brais LK; Cavanaugh ME; Rode AJ; Jean MG; Lizotte PH; Nazzaro MJ; Severgnini M; Zheng H; Fuchs CS; Enzinger PC; Bass AJ J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593617 [TBL] [Abstract][Full Text] [Related]
34. Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer. Fujiwara M; Fujiwara R; Urasaki T; Oguchi T; Komai Y; Numao N; Yamamoto S; Yonese J; Yuasa T Anticancer Res; 2022 Apr; 42(4):2045-2051. PubMed ID: 35347027 [TBL] [Abstract][Full Text] [Related]
35. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578 [TBL] [Abstract][Full Text] [Related]
36. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab. Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304 [TBL] [Abstract][Full Text] [Related]
37. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Yamamoto Y; Yatsuda J; Shimokawa M; Fuji N; Aoki A; Sakano S; Yamamoto M; Suga A; Tei Y; Yoshihiro S; Kitahara S; Nagao K; Takai K; Kamiryo Y; Akao J; Yamaguchi S; Oba K; Shimabukuro T; Matsumoto H; Kamba T; Matsuyama H Int J Clin Oncol; 2021 Jan; 26(1):169-177. PubMed ID: 32948925 [TBL] [Abstract][Full Text] [Related]
38. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Fujiwara Y; Karol AB; Joshi H; Reford E; Izadmehr S; Doroshow DB; Galsky MD Crit Rev Oncol Hematol; 2024 May; 197():104352. PubMed ID: 38614269 [TBL] [Abstract][Full Text] [Related]
39. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Zhang T; Harrison MR; O'Donnell PH; Alva AS; Hahn NM; Appleman LJ; Cetnar J; Burke JM; Fleming MT; Milowsky MI; Mortazavi A; Shore N; Sonpavde GP; Schmidt EV; Bitman B; Munugalavadla V; Izumi R; Patel P; Staats J; Chan C; Weinhold KJ; George DJ Cancer; 2020 Oct; 126(20):4485-4497. PubMed ID: 32757302 [TBL] [Abstract][Full Text] [Related]
40. STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer. Fuchizawa H; Ando K; Motoi N; Iizuka T; Inoue M; Mitani K; Sano Y; Takenobu H; Haruta M; Onuki R; Matsuoka Y; Kamijo T; Kageyama Y Anticancer Res; 2024 May; 44(5):1925-1930. PubMed ID: 38677727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]